

July 01, 2020

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	--

**Sub: Update on Acquisition of foreign entity in South Africa**

**Ref: Our disclosure dated September 18, 2019 given under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**



Dear Sirs,

Further to our disclosure dated September 18, 2019 regarding the acquisition of 100% shares of Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary company of Pharmacare Limited t/a Aspen Pharmacare, South Africa, we wish to update that the 100% shares of Phekolong Pharmaceuticals Pty. Ltd. have been acquired by the Company and Phekolong Pharmaceuticals Pty. Ltd. has now become the wholly-owned subsidiary of the Company (i.e, Laurus Labs Limited).

This is for your information and record.

Yours faithfully,

**For Laurus Labs Limited**

**G. Venkateswar Reddy**  
**Company Secretary**